DLCBL cases presenting high co‐expression of MYC and the anti‐apoptotic BCL2 protein show inferior prognosis [87, 88, 89, 90], which gets even worse in the subgroup historically known as ‘double hit lymphomas’ (DHL), a small subset (around 5% of total DLBCL) featuring concurrent chromosomal translocations targeting both MYC and BCL2 [89, 91, 92]. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.